$4.97
0.040.81%
Últ. Act.: Nov 12, 7:24 AM
Clover Health Investments rose 98.0% from $2.51 to $4.97, ahead of the S&P 500's +11.2%. Its worst day was Sep 15 (−8.6%), and its low came Apr 1 at $1.70.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Clover Health Investments shares rose 10.6%, while the S&P 500 fell 0.5%.
+10.6% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
EPS of $-0.10 missed the $-0.07 estimate on $487.7M revenue (est. $469.2M); FY revenue guidance of $2.8B–$2.9B against the $2.4B consensus.
−2.8% · S&P 500 −0.5%
Clover Health Investments closed at its lowest level of the year, 32.3% below where the year started.
−3.4% · S&P 500 +0.8%
EPS of $0.05 missed the $0.06 estimate on $749.2M revenue (est. $713.5M); FY revenue guidance of $2.8B–$2.9B against the $2.9B consensus.
+5.2% · S&P 500 −0.3%
Clover Health Investments shares rose 16.4%, while the S&P 500 rose 0.6%.
+16.4%, the year's best day · S&P 500 +0.6%
On June 9, 2026, CMS informed Clover that, consistent with the Court’s order, it has recalculated Clover’s 2026 Star Rating as 4.5 Stars, and has instructed Clover to submit alternate bids at 4.5 Stars.
+14.0%, on 26M shares, the year's heaviest volume · S&P 500 −1.6%
Clover Health Investments closed at its highest level of the year, 115.5% above where the year started.
+3.8% · S&P 500 −0.7%
EPS of $0.05 beat the $0.04 estimate on $743.2M revenue (est. $728.3M); FY revenue guidance of $2.9B–$3.0B against the $2.9B consensus.
+12.6% · S&P 500 −0.2%
EPS of $0.01 beat the $0.01 estimate on $759.3M revenue (est. $740.1M); FY revenue guidance of $3.0B–$3.0B against the $3.0B consensus.
−4.5% · S&P 500 −4.4%
Where it ended: a close of $4.97 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $-0.03, revenue est. $730.7M).
Nothing in the past 12 months.
All CLOV dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CLOV and SPY from Benzinga historical bars. Not investment advice.